State-of-the-Art Clinical Symposium
About the Event
Date:April 24–26, 2026
Location:Rosemont, IL
Credit:CME: TBA, ABIM & ABP MOC: TBA
On Demand:To Be Announced
During the State-of-the-Art Clinical Symposium (SOTA), key opinion leaders will deliver a range of content in areas such as therapeutic developments, recent research findings, and scientific advances, in an environment conducive to dialogue and networking.
Target Audience
Rheumatologists (physicians) in clinical care and/or research, fellows in training, division directors, program directors, assistant program directors, physician assistants, nurse practitioners, pharmacists, nurses, and epidemiologists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recognize and differentiate the clinical presentations and phenotypes of patients with complex rheumatic diseases including relapsing polychondritis, IgG4-related disease, and hypermobility syndromes to enhance diagnostic accuracy and individualized patient care.
- Discuss the most up-to-date evidence-based treatment approaches including novel therapies, in the management of a variety of rheumatic diseases including relapsing polychondritis, osteoporosis, and spondyloarthritis.
- Discuss and implement current recommendations regarding pregnancy and reproductive health issues pertinent to women and men with rheumatic disease.
- Summarize and apply guidelines for cancer screening in myositis, with a focus on identifying specific subtypes that necessitate more intensive monitoring, to enhance early detection and improve patient outcomes in this vulnerable population.
See information from the 2025 meeting in the State-of-the-Art Clinical Symposium 2025 section below.
Program Schedule & Syllabi
To Be Announced
Registered attendees can access the syllabi during the meeting and until 11:59 PM ET on December 31, 2025. To access syllabi, login and go to My Learning.
Registration Fees
To Be Announced
Press Registration
The American College of Rheumatology welcomes members of the press to write about research presented at our meetings. Complimentary registration is provided to approved members of the press to allow them to attend sessions on site.
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
CME
ACCME Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
See the ACR’s CME Mission Statement. For more information, download the AMA PRA Booklet.
AMA Designation Statement
The American College of Rheumatology designates this Live Activity for a maximum of (to be announced) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME credit must be claimed by December 31, 2026.
MOC
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to (to be announced) MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.
MOC points must be claimed by December 31, 2026.
Instructions to Claim CE/MOC Credit
Credit claiming is available after the activity starts.
See instructions to claim credit on the CME & MOC page.
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
- SOTA 2026 Financial Relationships Disclosures (to be announced)
- View ACR's ACCME disclosure practices
See 2025 disclosures in the 2025 meeting section below.
The State-of-the-Art Clinical Symposium 2025 was an in-person only event that took place April 4–6 in Chicago, IL.
Target Audience
Rheumatologists (physicians) in clinical care and/or research, fellows in training, division directors, program directors, assistant program directors, physician assistants, nurse practitioners, pharmacists, nurses, and epidemiologists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recognize and differentiate the clinical presentations and phenotypes of patients with complex rheumatic diseases including relapsing polychondritis, IgG4-related disease, and hypermobility syndromes to enhance diagnostic accuracy and individualized patient care.
- Discuss the most up-to-date evidence-based treatment approaches including novel therapies, in the management of a variety of rheumatic diseases including relapsing polychondritis, osteoporosis, and spondyloarthritis.
- Discuss and implement current recommendations regarding pregnancy and reproductive health issues pertinent to women and men with rheumatic disease.
- Summarize and apply guidelines for cancer screening in myositis, with a focus on identifying specific subtypes that necessitate more intensive monitoring, to enhance early detection and improve patient outcomes in this vulnerable population.
Program Schedule & Syllabi
State-of-the-Art Clinical Symposium 2025 Program Schedule
Registered attendees can access the syllabi during the meeting and until 11:59 PM ET on December 31, 2025. To access syllabi, login and go to My Learning.
CE & MOC Information
CME
ACCME Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
See the ACR’s CME Mission Statement. For more information, download the AMA PRA Booklet.
AMA Designation Statement
The ACR designates this blended learning activity encompassing live and on demand activity for a maximum of 10.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME credit must be claimed by December 31, 2025 at 11:59 PM.
MOC
MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.
MOC points must be claimed by December 31, 2025 at 11:59 PM.
Financial Relationships Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
Acknowledgement of Commercial Support
The ACR thanks Janssen Scientific Affairs, LLC for their unrestricted educational grant in support of the State-of-the-Art Clinical Symposium 2025.